RU2013111676A - Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение - Google Patents

Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение Download PDF

Info

Publication number
RU2013111676A
RU2013111676A RU2013111676/15A RU2013111676A RU2013111676A RU 2013111676 A RU2013111676 A RU 2013111676A RU 2013111676/15 A RU2013111676/15 A RU 2013111676/15A RU 2013111676 A RU2013111676 A RU 2013111676A RU 2013111676 A RU2013111676 A RU 2013111676A
Authority
RU
Russia
Prior art keywords
zwittergent
polypeptide
seq
lipid particle
solution
Prior art date
Application number
RU2013111676/15A
Other languages
English (en)
Russian (ru)
Inventor
Мартин БАДЕР
Моника Бенер
Антон ЙОХНЕР
Губерт КЕТТЕНБЕРГЕР
Зильке МОЛЬ
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2013111676A publication Critical patent/RU2013111676A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
RU2013111676/15A 2010-08-30 2011-08-25 Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение RU2013111676A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10008994.5 2010-08-30
EP10008994 2010-08-30
PCT/EP2011/064601 WO2012028525A2 (fr) 2010-08-30 2011-08-25 Procédé de production d'une particule lipidique, particule lipidique elle-même et son utilisation

Publications (1)

Publication Number Publication Date
RU2013111676A true RU2013111676A (ru) 2014-10-10

Family

ID=44509389

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013111676/15A RU2013111676A (ru) 2010-08-30 2011-08-25 Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение

Country Status (9)

Country Link
EP (1) EP2611417A2 (fr)
JP (1) JP2013538205A (fr)
KR (1) KR20130117760A (fr)
CN (1) CN103068369A (fr)
BR (1) BR112013004401A2 (fr)
CA (1) CA2807441A1 (fr)
MX (1) MX2013001539A (fr)
RU (1) RU2013111676A (fr)
WO (1) WO2012028525A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026803A1 (fr) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Procédé de chromatographie d'échange de cations et d'anions
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
EP0972838B1 (fr) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Système de sélection par complémentation d' une auxotrophie en absence d'antibiotique chez E. coli
EP1276754A4 (fr) 2000-04-14 2005-04-06 Nuvelo Inc Matieres et procedes relatifs au metabolisme lipidique
CA2428114C (fr) * 2000-11-10 2013-07-23 Proteopharma Aps Analogues d'apolipoproteine
EP1382614A1 (fr) * 2002-07-15 2004-01-21 Bayer HealthCare AG Procédé de purification de l'interleukine-4 et ses muteines
CA2443365C (fr) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methodes de production par recombinaison de peptides antifusiogenes
US20040180445A1 (en) * 2003-03-12 2004-09-16 Domanico Michael J. Methods and compositions for purification of nucleic acid from a host cell
DK1486571T3 (da) 2003-06-12 2006-04-18 Hoffmann La Roche Fremgangsmåde til rekombinant fremstilling af polypeptider
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
BRPI0417938A (pt) 2003-12-30 2007-04-17 Wyeth Corp formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada
WO2005084642A1 (fr) 2004-01-28 2005-09-15 Biodelivery Sciences International, Inc. Compositions d'apoproteines cochleaires
US20060110788A1 (en) * 2004-10-01 2006-05-25 Invitrogen Corporation Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
US20060214104A1 (en) * 2004-10-26 2006-09-28 Invitrogen Corporation Compositions and methods for analyzing biomolecules using mass spectroscopy
US20060160721A1 (en) 2004-12-22 2006-07-20 Baylor College Of Medicine Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
EP1896074A4 (fr) 2005-05-25 2009-04-22 Liponex Inc Compositions pharmaceutiques pour traiter ou prevenir une maladie coronarienne
EP2537526A1 (fr) 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Méthode et composé pour le traitement des sténoses valvulaires
EP2069487B1 (fr) * 2006-07-25 2014-03-19 Agilent Technologies, Inc. Detergents zwitterioniques pour le stockage et l'utilisation d'adn polymerases
FR2915490B1 (fr) * 2007-04-26 2011-10-28 Univ Joseph Fourier Grenoble I Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire
JP2010539995A (ja) * 2007-10-08 2010-12-24 アナフォア インコーポレイテッド 三量体ＩＬ−１Ｒａ
US8999320B2 (en) 2008-01-30 2015-04-07 The Rockefeller University Nanoscale bound bilayers, methods of use and production
CA3013503A1 (fr) 2008-04-25 2009-10-29 Northwestern University Nanostructures appropriees pour la sequestration du cholesterol et d'autres molecules

Also Published As

Publication number Publication date
MX2013001539A (es) 2013-03-18
WO2012028525A3 (fr) 2012-10-26
BR112013004401A2 (pt) 2016-05-17
CA2807441A1 (fr) 2012-03-08
WO2012028525A2 (fr) 2012-03-08
JP2013538205A (ja) 2013-10-10
KR20130117760A (ko) 2013-10-28
EP2611417A2 (fr) 2013-07-10
CN103068369A (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
RU2013111678A (ru) Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
CN103992384B (zh) 一种大黄鱼鱼骨胶原肽及其制备方法和用途
Murphy et al. Fasciola hepatica Extracellular Vesicles isolated from excretory-secretory products using a gravity flow method modulate dendritic cell phenotype and activity
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
WO2012069836A3 (fr) Complexe biologiquement actif et sa préparation
RU2019108268A (ru) Варианты химозина с улучшенными молокосвертывающими свойствами
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
JP2016505545A5 (fr)
RU2009117170A (ru) Высушенные восстановленные везикулы для фармацевтического применения
UA107571C2 (xx) Фармацевтична композиція
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
JP2015501656A5 (fr)
RU2534564C3 (ru) Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
CA2481936A1 (fr) Compositions d'un isolat de proteines de canola
MX2013002145A (es) Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma.
CA2846598A1 (fr) Traitement de maladie degenerative articulaire
EA201000860A1 (ru) С-с-алкилимидазолбисфосфонаты
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
RU2013111676A (ru) Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
RU2014102778A (ru) Белковый продукт канолы с низким содержанием фитиновой кислоты ("c702")
CA2515392A1 (fr) Particules de type virosome
RU2014107467A (ru) Ингибитор тирозиназы, полученный с использованием сухого порошка из дождевых червей, и способ его получения
JP2023520790A (ja) ウシ乳エキソソーム生成物および方法、栄養組成物、ならびに治療方法
WO2011009991A3 (fr) Micelles pic dendritiques comprenant des protéines bioactives
BR112012022292A2 (pt) método para produção da proteína recombinante interferon solúvel sem desnaturação.

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20151214